Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

Recruiting

• Conditions: Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm

• Registration Number: NCT06353191
• Lead Sponsor: Mayo Clinic

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-4-3
• Last Update Posted: 23 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

Inclusion Criteria:<br><br> - 18 years of age or older<br><br> - Treated for any malignancy with any type of chemotherapy including oral, parenteral<br> therapy and immunotherapy<br><br> - One of the following:<br><br> - Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart<br> failure, asymptomatic reduced systolic function, acute coronary syndrome,<br> myocardial infarction, critical limb ischemia, cardiac arrhythmias or<br> myocarditis possibly related to prior cancer treatment<br><br> - OR completed chemotherapy with no cardiotoxicity at least two years post<br> treatment<br><br> - OR Patients with cancer who will be initiating systemic therapy with<br> potentially cardiotoxic medications. This will include chemotherapy,<br> immunotherapy, targeted therapy that have been associated with cardiac toxicity<br><br> - An understanding of the protocol and its requirements, risks, and discomforts<br><br> - The ability and willingness to sign an informed consent<br><br>Exclusion Criteria:<br><br> - Inability on the part of the patient to understand the informed consent or be<br> compliant with the protocol

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Collection of biospecimens from patients who developed cardiac toxicity (CRCT) or who are at high risk for developing CRCT